News & Updates

Show Multimedia Only

Resmetirom demos potential in NASH

18 Jul 2022 by

Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.

Resmetirom demos potential in NASH

18 Jul 2022

PPI use not linked to cardiovascular disease risk

18 Jul 2022

The association between proton pump inhibitor (PPI) use and increased cardiovascular disease risk, as seen in many observational studies, is probably caused by residual confounding related to conditions with PPI treatment instead of a true correlation, as suggested by negative findings in a self-controlled case series (SCCS) study.

PPI use not linked to cardiovascular disease risk

18 Jul 2022

Eosinophilic esophagitis patients at greater risk of later psychiatric disorder

17 Jul 2022

The risk of psychiatric disease is higher in individuals with eosinophilic esophagitis (EoE) compared to their siblings and the general population, reveals a study. This risk must be addressed in clinical care to detect, prevent, and treat comorbidity.

Eosinophilic esophagitis patients at greater risk of later psychiatric disorder

17 Jul 2022

Post-surgery recurrence more likely in right- vs left-sided colon cancer

16 Jul 2022

The risk of recurrence after curative resection appears to be higher for stage II right-sided colon cancer, reports a recent study.

Post-surgery recurrence more likely in right- vs left-sided colon cancer

16 Jul 2022

Nonoperative management safe, feasible after complete response in rectal cancer

15 Jul 2022

Patients with locally advanced rectal cancer who achieve complete response (CR) following sequential short-course radiation therapy (SCRT) and chemotherapy appear to benefit from nonoperative management (NOM) with a watch-and-wait strategy, which presents evidence for good anorectal functions, results of a study have shown.

Nonoperative management safe, feasible after complete response in rectal cancer

15 Jul 2022

GI practitioners cease PPI use in patients due to concerns of side effects

15 Jul 2022

Discontinuation of proton pump inhibitor (PPI) use remains prevalent, even within a group of mostly academic gastroenterology (GI) practitioners, despite evidence suggesting the safety of long-term PPI use without routine monitoring, a study has shown.

GI practitioners cease PPI use in patients due to concerns of side effects

15 Jul 2022

Aspirin use lowers risk of liver cancer

14 Jul 2022

A recent study has shown that use of aspirin can help reduce the risk of developing liver cancer.

Aspirin use lowers risk of liver cancer

14 Jul 2022

Antiplatelet drugs up bleeding, decompensation events in cirrhosis patients

14 Jul 2022

Use of antiplatelet (AP) medication appears to increase bleeding and decompensation events among privately insured patients with cirrhosis, a study has found. Use of nonsteroidal anti-inflammatory drug (NSAID) is also associated with significant early bleeding, but not decompensations. Anticoagulants (AC), on the other hand, are not associated with bleeding or decompensation outcomes.